Loading…
Tvardi Therapeutics, Inc. is projected to decline to $1.65 by 2027, a -18% move from its current price of $2.02. TVRD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.85 | $2.02 | $2.20 | -0.06% |
| Aug 6 | $1.79 | $2.02 | $2.28 | -0.12% |
| Aug 7 | $1.74 | $2.02 | $2.34 | -0.18% |
| Aug 8 | $1.70 | $2.02 | $2.39 | -0.24% |
| Aug 9 | $1.66 | $2.01 | $2.44 | -0.30% |
| Aug 10 | $1.63 | $2.01 | $2.48 | -0.36% |
| Aug 11 | $1.60 | $2.01 | $2.52 | -0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.60 | $2.01 | $2.52 | -0.42% |
| Week 2 | $1.45 | $2.00 | $2.76 | -0.85% |
| Week 3 | $1.35 | $1.99 | $2.96 | -1.27% |
| Week 4 | $1.26 | $1.99 | $3.13 | -1.69% |
| Week 5 | $1.19 | $1.98 | $3.29 | -2.11% |
| Week 6 | $1.13 | $1.97 | $3.44 | -2.52% |
| Week 7 | $1.07 | $1.96 | $3.58 | -2.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, oral, small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. Its lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics, Inc. (TVRD) is a healthcare company currently trading at $2.14 per share with a market capitalization of $20.08M and a market rank of 4861. The stock sits in the lower end of small-cap stocks by market cap, reflecting a niche clinical-stage biotechnology profile.
The current price and market position are complemented by a mixed price outlook across the forecast horizon. The year-by-year projections show a range of outcomes from neutral to bearish in the near term, turning more bullish in select later years, with notable upside by 2031 and beyond, culminating in a strong bullish outlook for 2050.
A major floor 25.7% below — a decisive break under it would weaken the trend.
The nearest floor, 25.7% below — buyers have tended to step in here.
The nearest ceiling, 147.5% above — a clean break opens room to run.
A major ceiling 215.2% above — clearing it would confirm fresh momentum.
Key TVRD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TVRD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.26 | Sell | $2.25 | Sell |
| MA 10 | $2.49 | Sell | $2.44 | Sell |
| MA 20 | $2.89 | Sell | $2.61 | Sell |
| MA 50 | $2.82 | Sell | $2.84 | Sell |
| MA 100 | $3.13 | Sell | $3.57 | Sell |
| MA 200 | $3.71 | Sell | $6.43 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.33 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -108.14 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -28.33 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.27 | Sell |
| Awesome (5,34) | -0.38 | Sell |
| Ultimate (7,14,28) | 13.76 | Buy |
| Momentum (10) | -1.10 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 2.03 | Sell |
| ADX (14) | 17.53 | Neutral |
| ATR (14) | 0.21 | Info |
The near-term technical posture is Bearish, with RSI(14) at 40 indicating modest momentum weakness. The stock trades below the 50-day simple moving average of $2.89 and far below the 200-day simple moving average of $3.93, pointing to continued near-term pressure.
Support is identified at $1.50 and resistance at $5.00, suggesting a wide trading range as buyers and sellers clash. Over the last 30 days, the price has fluctuated between $1.17 and $3.91, underscoring meaningful volatility given the 200% annualized volatility. These metrics imply heightened risk in the immediate horizon while the range leaves room for upside if sentiment shifts.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.50 | $2.02 | $2.64 | 0% | Neutral | |
| $1.20 | $1.65 | $2.44 | -18% | Bearish | |
| $1.26 | $1.84 | $2.91 | -9% | Neutral | |
| $1.07 | $1.64 | $2.72 | -19% | Bearish | |
| $1.15 | $1.86 | $3.21 | -8% | Neutral | |
| $1.63 | $2.75 | $4.93 | +36% | Bullish | |
| $1.46 | $2.57 | $4.75 | +27% | Bullish | |
| $1.24 | $2.28 | $4.32 | +13% | Neutral | |
| $1.20 | $2.29 | $4.47 | +14% | Neutral | |
| $1.04 | $2.06 | $4.12 | +2% | Neutral | |
| $1.43 | $3.17 | $6.94 | +57% | Bullish | |
| $3.13 | $6.96 | $16.00 | +244% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.50 | $2.02 | $2.52 | +0.00% |
| September 2026 | $1.59 | $1.93 | $2.44 | -4.62% |
| October 2026 | $1.55 | $1.91 | $2.47 | -0.81% |
| November 2026 | $1.61 | $2.01 | $2.64 | +4.98% |
| December 2026 | $1.57 | $1.98 | $2.64 | -1.46% |
Click any year to see its month-by-month TVRD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Tvardi Therapeutics, Inc.'s 2026 outlook centres on $2.02, within a $1.50 to $2.64 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, TVRD could reach as high as $2.44, with a base case around $1.65 and support toward $1.20 — roughly -18% from $2.02. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect TVRD to range from $1.26 to $2.91 through 2028. The $1.84 average target implies a -9% move from current prices. That is up +12% on the projected 2027 average. A consolidation phase looks the most probable path here.
The TVRD price prediction for 2029 points to an average of $1.64 (low $1.07, high $2.72) — a potential decline of -19% on today's $2.02. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2030, TVRD is projected to trade between $1.15 and $3.21, averaging $1.86 — a potential decline of -8% from today's $2.02. That is up +13% on the projected 2029 average. A consolidation phase looks the most probable path here.
Tvardi Therapeutics, Inc.'s 2031 outlook centres on $2.75, within a $1.63 to $4.93 range. That is up +48% on the projected 2030 average. That marks a +36% change versus current levels. Momentum favours further upside here.
By 2032, TVRD could reach as high as $4.75, with a base case around $2.57 and support toward $1.46 — roughly +27% from $2.02. Buyers look set to stay in control over this stretch.
Expect TVRD to range from $1.24 to $4.32 through 2033. The $2.28 average target implies a +13% move from current prices. That is -11% versus the projected 2032 average. Price action looks broadly range-bound.
The TVRD price prediction for 2034 points to an average of $2.29 (low $1.20, high $4.47) — a potential gain of +14% on today's $2.02. A consolidation phase looks the most probable path here.
In 2035, TVRD is projected to trade between $1.04 and $4.12, averaging $2.06 — a potential gain of +2% from today's $2.02. That is -10% versus the projected 2034 average. Price action looks broadly range-bound.
Tvardi Therapeutics, Inc.'s 2040 outlook centres on $3.17, within a $1.43 to $6.94 range. That is up +53% on the projected 2035 average. That marks a +57% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, TVRD could reach as high as $16.00, with a base case around $6.96 and support toward $3.13 — roughly +244% from $2.02. Momentum favours further upside here.
Investing $1,000 in TVRD today (≈ 495.049505 TVRD) could be worth
$3,443.23
+$2,443.23 (+244%) by 2050 · US Dollar
Based on the average projected TVRD price of $6.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TVRDwould be worth at today's price.
$1,000 invested in TVRD on Jul 31, 2025 (≈ 38.520803 TVRD) would be worth
$77.81
-$922.19 (-92.2%) today · 0.08× · US Dollar
Based on a TVRD entry price of $25.96 vs. today's $2.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.51 | $804.78 | -19.5% |
| 1 month ago | $1.95 | $1,035.9 | +3.6% |
| 3 months ago | $3.14 | $643.31 | -35.7% |
| 6 months ago | $3.99 | $506.27 | -49.4% |
| 1 year ago | $25.96 | $77.81 | -92.2% |
| All time (5.0y) ago | $450 | $4.49 | -99.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TVRD forecast.
Our base-case forecast reaches $4.00 around 2050.
Implied market cap at $4.00: $37.53M
The multi-year forecast presents a varied path with periods of softness followed by growth. For 2026, the min/max/avg are $1.50 / $2.78 / $2.14 with ROI 0 and sentiment Neutral. In 2027 the forecast shows a decline to a min of $1.28, an avg of $1.76, and a max of $2.61 with ROI -17.9 and sentiment Bearish, signaling continued near-term headwinds.
The outlook remains mixed through 2029 and 2030, with 2028 at min $1.34, avg $1.95, max $3.09 (ROI -8.8, Neutral) and 2030 at min $1.23, avg $1.98, max $3.43 (ROI -7.4, Neutral). Beginning 2031 the forecast turns more constructive: min $1.74, avg $2.94, max $5.27 (ROI 37.4, Bullish) and 2032 at min $1.53, avg $2.69, max $4.98 (ROI 25.9, Bullish).
The momentum strengthens into the 2040s with 2040 forecast at min $1.52, avg $3.37, max $7.39 (ROI 57.5, Bullish), and culminates in 2050 at min $3.29, avg $7.31, max $16.81 (ROI 241.6, Bullish). These figures imply meaningful upside potential in the longer term, balanced against notable volatility and downside risk in earlier years.
Tap a question to reveal the answer.
2030 - min $1.23, avg $1.98, max $3.43 with ROI -7.4% and sentiment Neutral.
Forecast shows volatility with mixed signals: some years are Bearish (e.g., 2027 ROI -17.9%; 2029 ROI -20%; 2030 ROI -7.4%), while later years turn Bullish (2031 ROI 37.4%; 2040 ROI 57.5%; 2050 ROI 241.6%). These projections are not guarantees and carry substantial uncertainty.
Yes. The forecasted high for 2031 is $5.27, suggesting a move above $5 could occur in that year.
The 30-day range is $1.17 to $3.91.
Current price is $2.14 and market cap is $20.08M.
Tvardi Therapeutics, Inc. Community Discussion
0Share your Tvardi Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.